| Name | Title | Contact Details |
|---|---|---|
Sara Naseri |
Chief Executive Officer | Profile |
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Canadian Light Source is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AmbioPharm is a Beech Island, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Timken Radiology is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.